Highlights in bladder cancer from ASCO 2022

Joaquim Bellmunt, MD, PhD, Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA, talks on his highlights in bladder cancer from the American Society of Clinical Oncology (ASCO) 2022 Meeting, mentioning the Phase II/III QUILT-3.032 (NCT03022825) multicenter trial investigating the IL-15 enhancer, N-803, in patients with non-muscle invasive bladder cancer who had failed treatment with Bacillus Calmette-Guerin (BCG). In this study, patients achieved an impressive 70% complete response rate with a duration of response (DoR) of almost 2 years. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.